Hiroyuki Gatanaga

Adaptation of HIV-1 to human leukocyte antigen class I

Yuka Kawashima, Katja Pfafferott, John Frater et al. · Nature · 2009 · 470 citations · Full text

Life Sciences, Immunology, Infectious Diseases +11

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens

K. Tsuchiya, Hiroyuki Gatanaga, Natsuo Tachikawa et al. · Biochemical and Biophysical Research Communications · 2004 · 272 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Successful Efavirenz Dose Reduction in HIV Type 1-Infected Individuals with Cytochrome P450 2B6 *6 and *26

Hiroyuki Gatanaga, Tsunefusa Hayashida, K. Tsuchiya et al. · Clinical Infectious Diseases · 2007 · 222 citations

Medicine, Pharmacokinetics, Pharmacology +17

Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection

Kazumoto Murata, Mai Asano, Akihiro Matsumoto et al. · Gut · 2016 · 190 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Amino Acid Substitutions in Gag Protein at Non-cleavage Sites Are Indispensable for the Development of a High Multitude of HIV-1 Resistance against Protease Inhibitors

Hiroyuki Gatanaga, Yasuhiro Suzuki, Hsinyi Tsang et al. · Journal of Biological Chemistry · 2002 · 161 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +16